Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Iterum Therapeutics Plc (ITRM) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Iterum Therapeutics Plc. Table 2 shows the detailed insider transactions. This company's CIK number is 1659323.
Total stock buying since 2018: $57,493,849.
Total stock sales since 2018: $51,435,902.
Total stock option exercises since 2018: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 15,000 | $10,860 | 0 | $0 | 0 | $0 |
| 2024 | 0 | $0 | 0 | $0 | 436,794 | $0 |
| 2023 | 65,000 | $110,000 | 0 | $0 | 66,398 | $0 |
| 2022 | 0 | $0 | 166,041 | $260,918 | 380,328 | $0 |
| 2021 | 0 | $0 | 20,772,405 | $50,271,031 | 0 | $0 |
| 2020 | 61,540 | $0 | 556,130 | $903,953 | 25,664 | $0 |
| 2019 | 0 | $0 | 0 | $0 | 36,924 | $0 |
| 2018 | 4,450,355 | $57,372,989 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 15,000 | $10,860 | 0 | $0 | 0 | $0 |
| 2024-08 | 0 | $0 | 0 | $0 | 436,794 | $0 |
| 2023-12 | 35,000 | $53,440 | 0 | $0 | 0 | $0 |
| 2023-11 | 30,000 | $56,560 | 0 | $0 | 0 | $0 |
| 2023-10 | 0 | $0 | 0 | $0 | 8,966 | $0 |
| 2023-07 | 0 | $0 | 0 | $0 | 4,575 | $0 |
| 2023-06 | 0 | $0 | 0 | $0 | 47,559 | $0 |
| 2023-04 | 0 | $0 | 0 | $0 | 3,340 | $0 |
| 2023-01 | 0 | $0 | 0 | $0 | 1,958 | $0 |
| 2022-12 | 0 | $0 | 3,365 | $4,441 | 0 | $0 |
| 2022-09 | 0 | $0 | 115,544 | $238,567 | 0 | $0 |
| 2022-06 | 0 | $0 | 0 | $0 | 147,192 | $0 |
| 2022-03 | 0 | $0 | 47,132 | $17,910 | 233,136 | $0 |
| 2021-02 | 0 | $0 | 20,619,949 | $50,007,284 | 0 | $0 |
| 2021-01 | 0 | $0 | 152,456 | $263,747 | 0 | $0 |
| 2020-10 | 61,540 | $0 | 0 | $0 | 0 | $0 |
| 2020-09 | 0 | $0 | 56,130 | $92,053 | 0 | $0 |
| 2020-07 | 0 | $0 | 0 | $0 | 14,258 | $0 |
| 2020-06 | 0 | $0 | 500,000 | $811,900 | 11,406 | $0 |
| 2019-05 | 0 | $0 | 0 | $0 | 36,924 | $0 |
| 2018-11 | 10,000 | $62,890 | 0 | $0 | 0 | $0 |
| 2018-10 | 58,000 | $353,800 | 0 | $0 | 0 | $0 |
| 2018-09 | 500 | $5,000 | 0 | $0 | 0 | $0 |
| 2018-08 | 3,500 | $32,684 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-08 | Dunne Michael W. | Buy | 15,000 | .72 | 10,860 |
| 2024-08-06 | Fishman Corey N. (Chief Executive Officer) | Option Ex | 82,613 | .00 | 0 |
| 2024-08-06 | Dunne Michael W. | Option Ex | 106,247 | .00 | 0 |
| 2024-08-06 | Hunt Ronald | Option Ex | 247,934 | .00 | 0 |
| 2023-12-22 | Dunne Michael W. (Director) | Buy | 25,000 | 1.40 | 35,000 |
| 2023-12-18 | Dunne Michael W. (Director) | Buy | 10,000 | 1.84 | 18,440 |
| 2023-11-22 | Dunne Michael W. (Director) | Buy | 20,000 | 2.04 | 40,700 |
| 2023-11-20 | Fishman Corey N. (Chief Executive Officer) | Buy | 10,000 | 1.59 | 15,860 |
| 2023-10-01 | Dunne Michael W. (Director) | Option Ex | 3,487 | .00 | 0 |
| 2023-10-01 | Hunt Ronald (Director) | Option Ex | 5,479 | .00 | 0 |
| 2023-07-01 | Dunne Michael W. (Director) | Option Ex | 1,779 | .00 | 0 |
| 2023-07-01 | Hunt Ronald (Director) | Option Ex | 2,796 | .00 | 0 |
| 2023-06-15 | Chin Mark (Director) | Option Ex | 15,853 | .00 | 0 |
| 2023-06-15 | Hecht Beth (Director) | Option Ex | 15,853 | .00 | 0 |
| 2023-06-15 | Dunne Michael W. (Director) | Option Ex | 15,853 | .00 | 0 |
| 2023-04-01 | Dunne Michael W. (Director) | Option Ex | 1,299 | .00 | 0 |
| 2023-04-01 | Hunt Ronald (Director) | Option Ex | 2,041 | .00 | 0 |
| 2023-01-01 | Dunne Michael W. (Director) | Option Ex | 761 | .00 | 0 |
| 2023-01-01 | Hunt Ronald (Director) | Option Ex | 1,197 | .00 | 0 |
| 2022-12-02 | Puttagunta Sailaja (Chief Medical Officer) | Sale | 3,365 | 1.32 | 4,441 |
| 2022-09-20 | Ahrens Brenton Karl (Director) | Sale | 7,246 | 1.78 | 12,912 |
| 2022-09-19 | Ahrens Brenton Karl (Director) | Sale | 15,000 | 1.76 | 26,475 |
| 2022-09-16 | Ahrens Brenton Karl (Director) | Sale | 15,000 | 1.90 | 28,545 |
| 2022-09-15 | Ahrens Brenton Karl (Director) | Sale | 15,000 | 2.02 | 30,269 |
| 2022-09-14 | Ahrens Brenton Karl (Director) | Sale | 15,000 | 2.10 | 31,455 |
| 2022-09-13 | Ahrens Brenton Karl (Director) | Sale | 15,000 | 2.14 | 32,115 |
| 2022-09-12 | Ahrens Brenton Karl (Director) | Sale | 15,000 | 2.31 | 34,605 |
| 2022-09-09 | Ahrens Brenton Karl (Director) | Sale | 15,000 | 2.31 | 34,725 |
| 2022-09-08 | Ahrens Brenton Karl (Director) | Sale | 3,298 | 2.26 | 7,466 |
| 2022-06-23 | Chin Mark (Director) | Option Ex | 36,798 | .00 | 0 |
| 2022-06-23 | Hecht Beth (Director) | Option Ex | 36,798 | .00 | 0 |
| 2022-06-23 | Dunne Michael W. (Director) | Option Ex | 36,798 | .00 | 0 |
| 2022-06-23 | Hunt Ronald (Director) | Option Ex | 36,798 | .00 | 0 |
| 2022-03-25 | Dunne Michael W. (Director) | Option Ex | 10,494 | .00 | 0 |
| 2022-03-18 | Hecht Beth (Director) | Option Ex | 7,642 | .00 | 0 |
| 2022-03-14 | Matthews Judith M. (Chief Financial Officer) | Sale | 47,132 | .38 | 17,910 |
| 2022-03-11 | Fishman Corey N. (Chief Executive Officer) | Option Ex | 215,000 | .00 | 0 |
| 2021-02-12 | Sarissa Capital Master Fund Ii Lp (10% Owner) | Sale | 10,619,949 | 2.27 | 24,107,284 |
| 2021-02-11 | Sarissa Capital Master Fund Ii Lp (10% Owner) | Sale | 10,000,000 | 2.59 | 25,900,000 |
| 2021-01-26 | Matthews Judith M. (Chief Financial Officer) | Sale | 33,868 | 1.73 | 58,591 |
| 2021-01-26 | Fishman Corey N. (President & CEO) | Sale | 85,445 | 1.73 | 147,819 |
| 2021-01-26 | Dunne Michael W. (Director) | Sale | 33,143 | 1.73 | 57,337 |
| 2020-10-27 | Dunne Michael W. (Chief Scientific Officer) | Buy | 61,540 | .00 | 0 |
| 2020-09-30 | Matthews Judith M. (Chief Financial Officer) | Sale | 56,130 | 1.64 | 92,053 |
| 2020-07-01 | Chin Mark (Director) | Option Ex | 5,703 | .00 | 0 |
| 2020-07-01 | Heron Patrick J (Director) | Option Ex | 2,852 | .00 | 0 |
| 2020-07-01 | Hunt Ronald (Director) | Option Ex | 5,703 | .00 | 0 |
| 2020-06-13 | Kelly David George (Director) | Option Ex | 11,406 | .00 | 0 |
| 2020-06-02 | Powell Michael | Sale | 400,000 | 1.61 | 642,800 |
| 2020-06-01 | Powell Michael | Sale | 100,000 | 1.69 | 169,100 |
| 2019-05-24 | Chin Mark (Director) | Option Ex | 6,154 | .00 | 0 |
| 2019-05-24 | Kelly David George (Director) | Option Ex | 6,154 | .00 | 0 |
| 2019-05-24 | Edick Paul R (Director) | Option Ex | 6,154 | .00 | 0 |
| 2019-05-24 | Heron Patrick J (Director) | Option Ex | 6,154 | .00 | 0 |
| 2019-05-24 | Ahrens Brenton Karl (Director) | Option Ex | 6,154 | .00 | 0 |
| 2019-05-24 | Healy James (Director) | Option Ex | 6,154 | .00 | 0 |
| 2018-11-30 | Kelly David George (Director) | Buy | 10,000 | 6.29 | 62,890 |
| 2018-10-30 | Chin Mark (Director) | Buy | 58,000 | 6.10 | 353,800 |
| 2018-09-04 | Dunne Michael W. (Chief Scientific Officer) | Buy | 500 | 10.00 | 5,000 |
| 2018-08-27 | Dunne Michael W. (Chief Scientific Officer) | Buy | 500 | 10.00 | 5,000 |
| 2018-08-24 | Dunne Michael W. (Chief Scientific Officer) | Buy | 500 | 10.00 | 5,000 |
| 2018-08-23 | Edick Paul R (Director) | Buy | 500 | 10.44 | 5,218 |
| 2018-08-17 | Fishman Corey N. (President & CEO) | Buy | 2,000 | 8.73 | 17,466 |
| 2018-05-30 | Chin Mark (Director) | Buy | 337,606 | 13.00 | 4,388,878 |
| 2018-05-30 | Matthews Judith M. (Chief Financial Officer) | Buy | 4,000 | 13.00 | 52,000 |
| 2018-05-30 | Canaan Partners X Llc (Director) | Buy | 506,656 | 13.00 | 6,586,528 |
| 2018-05-30 | Fhm Vii, L.p. (10% Owner) | Buy | 456,099 | 13.00 | 5,929,287 |
| 2018-05-30 | Mehra Anand | Buy | 500,000 | 13.00 | 6,500,000 |
| 2018-05-30 | Fishman Corey N. (President & CEO) | Buy | 3,000 | 13.00 | 39,000 |
| 2018-05-30 | Dunne Michael W. (Chief Scientific Officer) | Buy | 2,000 | 13.00 | 26,000 |
| 2018-05-30 | Ratcliffe Liam (10% Owner) | Buy | 662,677 | 13.00 | 8,614,801 |
| 2018-05-30 | Malik Shahzad (Director) | Buy | 236,984 | 13.00 | 3,080,792 |
| 2018-05-30 | Ahrens Brenton Karl (Director) | Buy | 506,656 | 13.00 | 6,586,528 |
| 2018-05-30 | Hunt Ronald (Director) | Buy | 662,677 | 13.00 | 8,614,801 |
| 2018-05-30 | Healy James (Director) | Buy | 500,000 | 13.00 | 6,500,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of ITRM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Iterum Therapeutics Plc (symbol ITRM, CIK number 1659323) see the Securities and Exchange Commission (SEC) website.